November 10, 1998Circulation
Associations Between Lipoproteins and the Progression of Coronary and Vein-Graft Atherosclerosis in a Controlled Trial With Gemfibrozil in Men With Low Baseline Levels of HDL Cholesterol
Why the study?
Does gemfibrozil improve angiographic progression of coronary and vein-graft atherosclerosis in men with low baseline HDL cholesterol who have undergone coronary bypass surgery?
Population
372 men who had undergone coronary bypass surgery, selected primarily for low baseline HDL cholesterol levels
Comparison
Gemfibrozil 1200 mg/d for 32 months vs Placebo
Design
RCT, randomized, placebo-controlled
Follow-up
32 months
Authors
Discussion
Loading...
Member takes
Implication
Refines post-bypass lipid risk stratification in low-HDL men; extends angiographic evidence on IDL/LDL versus HDL3 predictors.
Structured PICO
Does gemfibrozil improve angiographic progression of coronary and vein-graft atherosclerosis in men with low baseline HDL cholesterol who have undergone coronary bypass surgery?
P
Population
372 men who had undergone coronary bypass surgery, selected primarily for low baseline HDL cholesterol levels (corresponding to the lowest third for middle-aged men)
I
Intervention
Gemfibrozil 1200 mg/d for 32 months
C
Comparator
Placebo
O
Outcome
Global angiographic progression of coronary artery disease (taking into account changes in native segments and in bypass grafts)surrogate
In men with low HDL cholesterol after coronary bypass surgery, triglyceride-rich lipoproteins (especially IDL) predict angiographic CAD progression, while HDL3 is protective.
Cite This Study
Syvänne et al. (1998) studied this question.